Skip to content
Peptide research

Dermorphin

Also known as Dermorphone
Category
Muscle & Performance
Administration routes
Injectable
Regulatory status
Not FDA-approved

A frog-skin opioid peptide binding mu-opioid receptors at roughly 30 to 40 times morphine potency. Human evidence is limited to one small 1985 trial; longer-term safety data come mostly from animal and veterinary studies. It requires invasive spinal delivery to act centrally, carries risks of respiratory depression and dependence, and is already misused as a doping agent in horse racing. Not an approved human drug, with no legitimate research-grade supply.

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.

Overview

Dermorphin is a naturally occurring peptide made of seven amino acids, first isolated in 1981 from the skin of South American tree frogs. It is one of the most potent natural painkillers ever discovered — approximately 30 to 40 times more powerful than morphine in standard pain tests, and up to 2,000 times more potent when delivered directly to the brain. Dermorphin is notable for containing a D-amino acid, an extremely rare feature in animal-derived peptides. Although a single human trial in 1985 demonstrated superior pain relief compared to morphine, it was never developed as a pharmaceutical drug. It has gained notoriety for illicit use in horse racing as a performance-enhancing substance.

How it works in the body

Binds to mu-opioid receptors with 30-40 times the potency of morphine. It has limited blood-brain barrier penetration when administered systemically, requiring intrathecal delivery for central effects. It activates the same pain-relief pathways as natural endorphins, but with much stronger binding affinity. This produces potent analgesia and euphoria.

Research overview

Dermorphin was discovered by Vittorio Erspamer's group in 1981 at the University of Rome. It is a highly selective activator of mu-opioid receptors — the same receptors targeted by morphine and other opioid painkillers. A 1985 randomized clinical trial with active comparators tested dermorphin against morphine for post-surgical pain relief via spinal injection. Dermorphin produced significantly longer pain relief (43 hours vs. 34 hours for morphine vs. 11 hours for pentazocine), with 80% of dermorphin patients requiring no additional painkillers. Animal studies also showed less tolerance development: 65% of rats maintained pain relief after 4 days of continuous treatment compared to only 10% on morphine. Despite these promising results, no further clinical trials have been conducted in nearly 40 years. The peptide cannot cross the blood-brain barrier on its own, limiting it to spinal injection routes. Fewer than 600 papers have been published on dermorphin total.

Who researches Dermorphin?

Commonly researched by

  • People exploring pain management options

    Researched for analgesic or pain-modulating properties.

Important considerations for

  • Those with Opioid addiction or dependence

    Absolute

    Extremely potent mu-opioid agonist (30-40x morphine). High addiction potential.

  • Those with Respiratory depression risk

    Absolute

    Potent opioid activity can cause life-threatening respiratory depression.

  • Those with Concurrent opioid or sedative use

    Absolute

    Additive CNS depression risk. Can be fatal in combination.

Safety & interactions

Do not use if

  • Opioid addiction or dependence

    Absolute

    Extremely potent mu-opioid agonist (30-40x morphine). High addiction potential.

  • Respiratory depression risk

    Absolute

    Potent opioid activity can cause life-threatening respiratory depression.

  • Concurrent opioid or sedative use

    Absolute

    Additive CNS depression risk. Can be fatal in combination.

How to read the ratings

Benefits
= confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Risks
= level of concern: High · Moderate · Low · Theoretical
Interactions
= direction with this peptide: Protective / Synergistic · Caution · Neutral

Risk summary(10)

Rated by level of concern

  • Nausea and vomiting — Reported in up to 50% of patients in open-label studies; reducible to <20% with domperidone pretreatment

    High

    PMID 30538538 (J Pain Res 2018;11:2991-5, summarizing the Italian open studies preceding PMID 3831962); PMID 3831962

  • Urinary retention — 26% incidence in the 1985 clinical trial (comparable to morphine at 30%)

    Moderate

    PMID 3831962 (side-effect non-difference stated in primary abstract); PMID 30538538 (26%/30% figures)

  • Respiratory depression — Expected class effect of potent mu-opioid agonists; not specifically quantified for dermorphin in humans but a theoretical concern given extreme potency

    Moderate

    PMID 3831962; PMID 30538538 (J Pain Res 2018 — does not discuss respiratory depression); human infusion studies PMID 6633818, PMID 2997256; class effect: FDA opioid analgesic labeling

  • Tolerance and physical dependence — Demonstrated in animal models, though less pronounced than with morphine (65% vs 10% maintaining analgesia at 4 days continuous infusion)

    Moderate

    Rodent figures via PMID 30538538; cross-tolerance: PMID 3831961 (Peptides 1985;6 Suppl 3); mechanistic context: PMID 20394808

  • Excitation and cardiovascular effects — Intravenous administration in horses caused acute excitation and increased heart rate (resolved within 5 minutes)

    Low

    PMID 25376170 (Robinson MA, Guan F, McDonnell S, Uboh CE, Soma LR. J Vet Pharmacol Ther 2015;38(4), doi:10.1111/jvp.12179)

  • Cannot cross blood-brain barrier — Requires invasive intrathecal or intracerebroventricular administration, carrying inherent procedural risks (infection, headache, nerve damage)

    High

    PMID 30538538 (BBB statement); PMID 3831962; PMID 30986300 (Pain Med 2019;20(10):2077-9)

  • Endocrine disruption — Stimulates thyrotropin (TSH) secretion and decreases luteinizing hormone (LH) levels in humans

    Moderate

    PMID 6470436 (Roti et al., J Endocrinol Invest 1984 — TSH); PMID 3936026 (Petraglia et al., Peptides 1985 — LH); PMID 6633818 (degli Uberti et al., Neuroendocrinology 1983 — GH); PMID 2997256 (Degli Uberti et al., JCEM 1985 — metyrapone-evoked ACTH/beta-endorphin/beta-lipotropin)

  • Abuse potential — High potency mu-opioid agonist with significant abuse liability; already misused in horse racing

    Moderate

    PMID 23571464 (Guan F et al., Anal Bioanal Chem 2013 — equine doping-control assay, notes misuse from 2011); PMID 25376170 (equine PK/PD); PMID 30538538 (peripheral dosing does not cross the BBB)

  • Lack of safety data — Human evidence includes a 150-patient postoperative randomized trial and small endocrine studies; long-term safety remains unknown.

    High

    PMID 3831962; PMID 30538538 (J Pain Res 2018;11:2991-5); PMID 30986300 (Pain Med 2019;20(10):2077-9)

  • Naloxone reversal eliminates analgesia — While naloxone reverses adverse effects, it simultaneously abolishes all analgesic benefit

    Moderate

    PMID 30538538 (naloxone nullified analgesia); PMID 6470436; PMID 3936026; PMID 6633818

Interaction summary(8)

Rated by direction with this peptide

  • Benzodiazepines and other CNS depressants (sedative-hypnotics, gabapentinoids, general anesthetics)

    CautionHigh

    Additive respiratory and CNS depression is a boxed-warning-level class interaction for mu-opioid agonists, and dermorphin's only realistic use setting (perioperative or palliative intrathecal therapy, alongside anesthetics and sedatives) makes co-exposure the norm rather than the exception. No dermorphin-specific co-administration study exists — this is mechanism-based extrapolation from a very well-established class effect.

    FDA opioid analgesic class boxed warning on concomitant benzodiazepine use (2016 Drug Safety Communication); extrapolated to dermorphin — no dermorphin-specific interaction study published

  • Other mu-opioid agonists (morphine, fentanyl, hydromorphone, oxycodone)

    CautionModerate

    Two-way problem. Additive respiratory depression and sedation on the safety side; demonstrated bidirectional cross-tolerance on the efficacy side — morphine-tolerant rats showed reduced dermorphin analgesia and vice versa, so prior or concurrent opioid exposure will blunt dermorphin's effect while the safety risks still add up. The cross-tolerance evidence is rodent-only; the additive-depression concern is class pharmacology.

    PMID 3831961 (Broccardo M, Improta G. Cross-tolerance between dermorphin and morphine to analgesia and catalepsy in rats. Peptides 1985;6 Suppl 3); mu-opioid class pharmacology

  • Naloxone / naltrexone (opioid antagonists)

    ProtectiveModerate

    Naloxone reverses dermorphin's effects across the board in humans — it relieved persistent vomiting in the open intrathecal studies and blocked the TSH, LH and GH responses in the endocrine studies — so it is an effective rescue agent. But reversal is all-or-nothing in the published record: relieving the side effect also nullified the analgesia. Anyone on maintenance naltrexone would be expected to get no analgesic effect at all.

    PMID 30538538 (J Pain Res 2018;11:2991-5); PMID 6470436; PMID 3936026; PMID 6633818

  • Domperidone (and by extension other antiemetics)

    ProtectiveLow

    Domperidone pretreatment significantly lowered the incidence of nausea/vomiting with intrathecal dermorphin to under 20% without blunting analgesia, making it the only empirically validated adjunct in the entire dermorphin literature — it was written into the 1985 controlled trial protocol for that reason. Caveat: domperidone itself carries QT-prolongation and serious cardiac arrhythmia risk and is not approved for marketing in the US.

    PMID 30538538 (open studies preceding PMID 3831962; <20% figure quoted directly); FDA has not approved domperidone for US marketing

  • Anticholinergic drugs (antimuscarinics, tricyclics, some antihistamines)

    CautionLow

    Additive urinary retention is mechanistically expected on top of dermorphin's documented 26% retention rate after intrathecal dosing. No dermorphin-specific co-administration data exists; this is mechanism-based extrapolation, and the underlying event was transient and manageable in the trial setting.

    Retention rate 26% from PMID 30538538 / PMID 3831962; the additive interaction is mechanism-based extrapolation, not demonstrated

  • Anticoagulants and antiplatelet agents

    CautionHigh

    Not a pharmacological interaction with dermorphin itself but a route-driven one, and the most clinically consequential real-world interaction for this compound: dermorphin can only be delivered neuraxially, and neuraxial puncture under anticoagulation carries a serious spinal/epidural hematoma risk governed by strict ASRA timing guidelines. Severity is rated High on the consequence (paralysis) rather than on any dermorphin-specific data.

    ASRA Regional Anesthesia in the Patient Receiving Antithrombotic or Thrombolytic Therapy guidelines, 4th ed. (Reg Anesth Pain Med 2018;43:263-309); FDA boxed warning on epidural/spinal hematoma with low-molecular-weight heparins; route requirement from PMID 30538538

  • Endocrine testing and hormone-sensitive treatment (thyroid function tests, gonadotropin/fertility monitoring, GH and prolactin assays)

    CautionModerate

    Dermorphin acutely raises TSH and growth hormone, lowers LH (FSH unchanged, effect modulated by gonadal steroids), and suppresses metyrapone-stimulated ACTH/beta-endorphin/beta-lipotropin release in humans — all naloxone-reversible. It can therefore confound endocrine diagnostics in the hours around dosing. The chronic hypogonadism concern is class-based extrapolation only; no repeated-dose human data exists. Note the prolactin effect is the least well-documented of the group and should be treated as the weakest element of this entry.

    PMID 6470436 (TSH); PMID 3936026 (LH); PMID 6633818 (GH); PMID 2997256 (metyrapone-evoked ACTH/beta-endorphin/beta-lipotropin)

  • Alcohol

    CautionModerate

    Additive CNS and respiratory depression with any potent mu agonist. A general class caution rather than anything measured for dermorphin specifically — no dermorphin-alcohol study exists.

    Mu-opioid agonist class pharmacology / FDA labeling for opioid analgesics; no dermorphin-specific data

Known risks(10)

  • Nausea and vomiting — Reported in up to 50% of patients in open-label studies; reducible to <20% with domperidone pretreatment

  • Urinary retention — 26% incidence in the 1985 clinical trial (comparable to morphine at 30%)

  • Respiratory depression — Expected class effect of potent mu-opioid agonists; not specifically quantified for dermorphin in humans but a theoretical concern given extreme potency

  • Tolerance and physical dependence — Demonstrated in animal models, though less pronounced than with morphine (65% vs 10% maintaining analgesia at 4 days continuous infusion)

  • Excitation and cardiovascular effects — Intravenous administration in horses caused acute excitation and increased heart rate (resolved within 5 minutes)

  • Cannot cross blood-brain barrier — Requires invasive intrathecal or intracerebroventricular administration, carrying inherent procedural risks (infection, headache, nerve damage)

  • Endocrine disruption — Stimulates thyrotropin (TSH) secretion and decreases luteinizing hormone (LH) levels in humans

  • Abuse potential — High potency mu-opioid agonist with significant abuse liability; already misused in horse racing

  • Lack of safety data — Human evidence includes a 150-patient postoperative randomized trial and small endocrine studies; long-term safety remains unknown.

  • Naloxone reversal eliminates analgesia — While naloxone reverses adverse effects, it simultaneously abolishes all analgesic benefit

Drug interactions(8)

  • Other opioid agonists (morphine, fentanyl, oxycodone) — Additive respiratory depression and CNS depression; potentially fatal combination given dermorphin's extreme potency

    No interaction data available

  • Benzodiazepines (diazepam, midazolam) — Synergistic CNS and respiratory depression; high risk of fatal overdose

    No interaction data available

  • Naloxone and naltrexone — Opioid antagonists that reverse dermorphin effects; naloxone successfully reversed nausea in clinical trial but also eliminated analgesia

    No interaction data available

  • Domperidone — Used as pretreatment to reduce dermorphin-induced nausea/vomiting (reduced incidence from 50% to <20%)

    No interaction data available

  • MAO inhibitors — Theoretical risk of serotonin syndrome or hypertensive crisis as with other opioids

    No interaction data available

  • CNS depressants (alcohol, barbiturates, sedatives) — Enhanced sedation and respiratory depression

    No interaction data available

  • Thyroid medications — Dermorphin stimulates TSH release, potentially requiring dose adjustment of thyroid hormones

    No interaction data available

  • Hormonal therapies — Dermorphin decreases LH levels, potentially interfering with reproductive hormones and fertility treatments

    No interaction data available

Research & benefits

Evidence base

Evidence Level
Limited
Total Studies
Approximately 600 total publications (PubMed); 1 human RCT
Human Studies
1 randomized controlled trial in postoperative patients

A randomized postoperative clinical trial with active comparators (1985) demonstrated superior postoperative analgesia via intrathecal dermorphin versus intrathecal morphine and intramuscular pentazocine. Dermorphin provided 43-hour mean analgesia duration with 80% of patients needing no additional pain medication. No subsequent clinical trials have been conducted. Extensive preclinical data in rodents and horses confirm potent mu-opioid agonism. The 1985 clinical paper has received only ~15 citations, none from clinical researchers, representing a significant gap in translational development.

Researched for(6)

Rated by confidence in the evidence

  • Potent analgesia via mu-opioid receptor agonism

    Medium

    Animal assays found approximately 39–40 times morphine's potency; this is not a measured human potency ratio.

    PMID 3831962 (Basso N, Marcelli M, Ginaldi A, De Marco M. Intrathecal dermorphine in postoperative analgesia. Peptides 1985;6 Suppl 3:177-9) for the human analgesic effect; PMID 2161761 (mu-receptor binding, rat brain, Eur J Biochem 1990) for mechanism; review PMID 30538538 (Keppel Hesselink & Schatman, J Pain Res 2018;11:2991-5). PMID 7195758: Broccardo et al., British Journal of Pharmacology, 1981, measured 39-fold potency versus morphine in guinea-pig ileum and 40-fold in mouse vas deferens.

  • Prolonged postoperative pain relief (mean 43 hours from single intrathecal injection vs 34 hours for morphine)

    Medium

    Single 1985 randomized trial, never replicated, found significantly longer relief than morphine.

    PMID 3831962; PMID 30538538 (J Pain Res 2018;11:2991-5)

  • Reduced need for supplementary analgesics (only 22% of patients vs 58% for morphine, 88% for placebo)

    Medium

    Same 1985 trial; comparator was active pentazocine, not an inert placebo, never replicated.

    PMID 3831962; PMID 30538538 (J Pain Res 2018;11:2991-5) — 22%/58%/88% quoted directly

  • Shorter postoperative hospital stays (5.6 days vs 6.3 for morphine, 8.7 for the pentazocine control group)

    Low

    Both intrathecal groups had shorter stays than the pentazocine control group; superiority of dermorphin over morphine was not established.

    PMID 3831962; PMID 30538538

  • Lower tolerance development compared to morphine in animal models

    Low

    Rodent studies only; no human chronic-dosing data exist for tolerance comparison.

    Rodent tolerance figures via PMID 30538538 (J Pain Res 2018;11:2991-5); cross-tolerance: PMID 3831961 (Broccardo M, Improta G. Cross-tolerance between dermorphin and morphine to analgesia and catalepsy in rats. Peptides 1985;6 Suppl 3); mechanistic context only: PMID 20394808 (Macey et al., Neuroscience 2010)

  • High mu-opioid receptor selectivity with minimal kappa and delta receptor affinity

    Low

    Well-replicated receptor-binding property in rats; no direct human clinical outcome data.

    Primary: PMID 2161761 (Amiche et al., Eur J Biochem 1990). Analogue chemistry only, not direct support: PMID 2537427 (DALDA analogues, J Med Chem 1989); PMID 12472847 (affinity labels, J Pept Res 2003)

Benefits(6)

  • Potent analgesia via mu-opioid receptor agonism

    Broccardo et al. 1981, British Journal of Pharmacology; Multiple preclinical studies

  • Prolonged postoperative pain relief (mean 43 hours from single intrathecal injection vs 34 hours for morphine)

    1985 randomized controlled trial published in Peptides

  • Reduced need for supplementary analgesics (only 22% of patients vs 58% for morphine, 88% for placebo)

    1985 intrathecal postoperative pain RCT

  • Shorter postoperative hospital stays (5.6 days vs 6.3 for morphine, 8.7 for the pentazocine control group)

    1985 intrathecal postoperative pain RCT

  • Lower tolerance development compared to morphine in animal models

    Preclinical continuous infusion studies; 65% maintained analgesia at 4 days vs 10% on morphine

  • High mu-opioid receptor selectivity with minimal kappa and delta receptor affinity

    Multiple receptor binding studies; Negri et al. 1992, PNAS

Key studies(6)

  1. Pharmacological data on dermorphins, a new class of potent opioid peptides from amphibian skin

    Preclinical pharmacological characterizationIn vitro and in vivo animal modelsAcute studies

    Broccardo M, Erspamer V, Falconieri Erspamer G, Improta G, Linari G, Melchiorri P, Montecucchi PC

    British Journal of Pharmacology

    1981

    Dermorphin demonstrated 39x greater potency than morphine in the guinea-pig ileum assay, 40x on vas deferens. ICV administration in rats showed ED50 of 13-23 pmol/rat, representing 750-2,170x greater potency than morphine depending on assay.

  2. Negri L, Erspamer GF, Severini C, Potenza RL, Melchiorri P, Erspamer V

    Proceedings of the National Academy of Sciences (PNAS)

    1992

    Identified two mu-opioid receptor subtypes activated by dermorphin-related peptides: high-affinity (mediating antinociception) and low-affinity (mediating catalepsy). [Lys7-NH2]dermorphin was a potent analgesic; [Trp4,Asn7-NH2]dermorphin produced intense catalepsy.

  3. Rediscovery of old drugs: the forgotten case of dermorphin for postoperative pain and palliation

    Review and retrospective analysis of clinical dataReview of 1985 RCT and preclinical data

    Keppel Hesselink JM, Schatman ME

    Journal of Pain Research

    2018

    Argued that dermorphin's superior 1985 clinical results (43h analgesia vs 34h morphine, 80% no supplementary analgesics needed) were unjustly overlooked. Proposed revisiting dermorphin for intrathecal postoperative and palliative pain management.

  4. Pharmacokinetics and pharmacodynamics of dermorphin in the horse

    Pharmacokinetic study in horses10 horses72 hours observation

    Robinson MA, Guan F, McDonnell S, Uboh CE, Soma LR

    Journal of Veterinary Pharmacology and Therapeutics

    2015

    IV dermorphin (9.3 mcg/kg) showed distribution half-life 0.09h and elimination half-life 0.76h. IM bioavailability 47-100%. Detectable in plasma for 12h and urine for 48-72h. Caused excitation and increased heart rate after IV administration.

  5. Sinha B, Cao Z, Murray TF, Aldrich JV

    Journal of Medicinal Chemistry

    2009

    Developed dermorphin-based affinity labels with subnanomolar affinity for mu-opioid receptors, providing tools for receptor characterization and potential therapeutic development.

  6. Guan F, Uboh CE, Soma LR, Robinson M, Maylin GA, Li X

    Analytical and Bioanalytical Chemistry

    2013

    Developed and validated LC-MS/MS method for detecting dermorphin in equine plasma and urine at sub-nanogram levels for anti-doping enforcement in horse racing.

Regulation & availability

Why researchers look at it

A 1985 randomized trial showed 43 hours of post-surgical pain relief versus 34 for morphine, with 80% of patients needing no additional painkillers — and animal data suggested far less tolerance buildup (65% maintained relief after 4 days versus 10% on morphine). No follow-up human trials have been conducted in nearly 40 years despite these remarkable results. If modern drug development revisited dermorphin's unique mu-opioid profile, it could inform next-generation analgesics.

Estimated cost
Controlled substance in many jurisdictions — not legally available
FDA status
Not FDA approved. No FDA-approved dermorphin product was identified, and it is not eligible for compounding in the US. Public records do not establish whether an IND or NDA has ever been submitted; IND existence is generally confidential unless publicly acknowledged. In horse racing, ARCI classifies dermorphin as a Class 1, Penalty A substance.
WADA status
Dermorphin and its analogues are included in WADA's 2026 Monitoring Program for in-competition use, not listed as prohibited S7 narcotics. Monitoring is not prohibition. Separately, ARCI classifies dermorphin as a Class 1, Penalty A substance in horse racing.
Prescribability
No — Dermorphin is not approved for human medical use by any regulatory agency. It is not available by prescription and has no marketing authorization.
Availability
Not commercially available for human medical use. It has no pharmaceutical formulation approved for clinical use in any country. The compound has been available on black markets for illicit use in horse racing. Traditional use exists among Amazonian indigenous peoples (Matses tribe) as part of Kambo/Sapo frog secretion ceremonies, though this involves crude skin secretions containing multiple bioactive peptides, not purified dermorphin.

International status

  • EU

    Not approved

  • US

    Not FDA-approved

  • Worldwide

    No regulatory approval in any jurisdiction

Sources & FAQs

Research sources(9)

  1. PubMed — Approximately 600 publications on dermorphin (search term: 'dermorphin')
  2. PMC — Full-text articles including Negri et al. 1992 (PMC49674) and Keppel Hesselink and Schatman 2018 (PMC6260176)
  3. British Journal of Pharmacology — Original pharmacological characterization (Broccardo et al. 1981)
  4. Proceedings of the National Academy of Sciences (PNAS) — Mu receptor subtype study (Negri et al. 1992)
  5. Journal of Pain Research — Clinical review (Keppel Hesselink and Schatman, 2018)
  6. Journal of Veterinary Pharmacology and Therapeutics — Equine pharmacokinetics (Robinson et al. 2015)
  7. Analytical and Bioanalytical Chemistry — Doping detection methodology (Guan et al. 2013)
  8. Wikipedia — General reference and chemical data
  9. WADA Prohibited List (2026) — Regulatory classification

Frequently asked questions(6)

What is dermorphin and where does it come from?

Dermorphin is a 7-amino-acid opioid peptide (H-Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH2) naturally produced in the skin of South American tree frogs of the genus Phyllomedusa. It was first isolated in 1981 by Italian researchers led by Vittorio Erspamer. It is unique among animal peptides for containing a D-amino acid (D-alanine) at position 2.

How potent is dermorphin compared to morphine?

Dermorphin is approximately 30-40 times more potent than morphine in standard peripheral tissue assays (guinea-pig ileum). When administered directly into the brain (intracerebroventricularly), it is 750-2,170 times more potent than morphine depending on the pain test used. In a human trial, a single intrathecal dose provided 43 hours of postoperative analgesia.

Can dermorphin be prescribed for pain management?

No. Dermorphin is not approved for medical use by any regulatory agency worldwide. It has never completed the drug development pipeline. A postoperative randomized trial was conducted in 1985, alongside other small human endocrine studies, and despite promising results, no further clinical development occurred. It remains a research compound only.

Why was dermorphin never developed into a drug despite positive clinical results?

Several factors contributed: (1) it cannot cross the blood-brain barrier, requiring intrathecal administration; (2) the 1985 clinical results were published in a specialized peptide journal with limited clinical readership; (3) peptide-based drugs had limited commercial appeal in the 1980s; (4) the intrathecal route was considered unfashionable compared to oral/injectable formulations. Modern intrathecal pump technology could potentially overcome the route-of-administration limitation.

Why is dermorphin associated with horse racing scandals?

Dermorphin was used illegally as a performance-enhancing drug in horse racing, first detected around 2011. Its potent analgesic effects mask pain, allowing horses to run harder than they safely should, putting both horses and jockeys at risk. It is classified as a Class I prohibited substance in equine sports. Its peptide structure initially made it difficult to detect by standard drug testing, though LC-MS/MS methods have since been developed.

Is dermorphin the same as Kambo?

No, but they are related. Kambo (or Sapo) is a traditional Amazonian practice using the crude skin secretion of Phyllomedusa bicolor frogs, which contains dermorphin among many other bioactive peptides (including deltorphins, phyllocaerulein, and others). Kambo produces intense physiological effects including vomiting, swelling, and tachycardia. Purified dermorphin is a single isolated peptide, distinct from the complex secretion mixture.